Therapeutic potential of ALKB homologs for cardiovascular disease - 28/10/20
páginas | 11 |
Iconografías | 4 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | ALKB homologs can regulate the physiological and pathological processes of CVDs. |
• | ALKBH1, ALKBH8 and FTO are associated with the process of oxidative stress and inflammation in CVDs. |
• | ALKBH1 might be a potential biomarker for AS, and developing its inhibitors can be benefit to AS therapy. |
• | FTO agonist may be able to improve MI-induced heart failure. |
• | ALKBH family might be a promising target for CVDs therapy. |
Abstract |
Cardiovascular diseases (CVDs) are the leading causes of human death. Recently, ALKB homologs, including ALKBH1−8 and FTO, have been found to have a variety of biological functions, such as histone demethylation, RNA demethylation, and DNA demethylation. These functions may regulate the physiological and pathological processes of CVDs, including inflammation, oxidative stress, cell apoptosis, and mitochondrial, endothelial, and fat metabolism dysfunction. In the present review, we summarize the biological functions of ALKB homologs and the relationship between the ALKB homologs and CVDs. Importantly, we discuss the roles of ALKB homologs in the regulation of oxidative stress, inflammation, autophagy, and DNA damage in CVDs, as well as the practical applications of ALKB homologs inhibitors or agonists in treating CVDs. In conclusion, the ALKBH family might be a promising target for CVDs therapy.
El texto completo de este artículo está disponible en PDF.Abbreviations : CVDs, AS, MI, CHD, 2OG, FTO, DSBH, RRM, CTD, AP, f5C34, PCNA, N3-EtdT, ASCC, tDRs, NM II, ATRN, ASXL1, GSC, LCs, CCNA2, CDK2, STAT1, PPAR-γ, GR, NAFLD, GC, MMP13, SFPQ, MMS, mcm5U, MEFs, MIAT, VSMCs, AngII, ATG, TFEB, PARP1, NAD+, RyR2, SERCA2a, Ca2+, SR, MYH6, AMPK, ROS, O2−, ONOO−, OH−, H2O2, HOCl
Keywords : Cardiovascular diseases, ALKB homologs, RNA demethylation, DNA demethylation, Oxidative stress, Therapy
Esquema
Vol 131
Artículo 110645- novembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?